Research Watch, Arthritis Drugs, June 2007

1
ARTICLE: 'Effectiveness of Adalimumab for Rheumatoid Arthritis in Patients with a History of TNF-antagonist Therapy in Clinical Practice'

JOURNAL: Rheumatology (Oxford) 2007 May 15; [Epub ahead of print]

SUMMARY: ReAct (Research in Active Rheumatoid Arthritis) was a large, open-label trial that enrolled adults with active RA who had previously been treated with traditional DMARDs or biological response modifiers. Of 6,610 patients, 899 had a history of etanercept and/or infliximab therapy; these patients experienced substantial clinical benefit from adalimumab treatment. There was no statistically significantly increased risk of serious infections in patients who received prior TNF antagonists …